10-Q: National Research Corporation Reports Q1 2025 Results; Appoints New CEO

National Research Corporation (NRC Health) announces its Q1 2025 financial results, including a decrease in revenue and the appointment of Trent Green as the new CEO effective June 1, 2025.

Summary

• National Research Corporation (NRC Health) reported a decrease in revenue for the first quarter of 2025, with revenue declining to $33.551 million from $35.313 million in the same period of 2024.
• The company's operating income also saw a slight decrease, falling from $8.760 million to $8.596 million.
• Basic and diluted earnings per share both decreased to $0.25, compared to $0.27 in the first quarter of the previous year.
• Recurring Contract Value (TRCV) decreased year-over-year but increased sequentially from the previous quarter.
• The Board of Directors appointed Trent Green as the new Chief Executive Officer, effective June 1, 2025.
• The company recognized a loss on extinguishment of debt of $67,000 related to the new credit agreement.
• The company repurchased 307,709 shares of its common stock for an aggregate of $5.0 million during the quarter.
• The company estimates future costs related to headquarters building renovations to be $3.7 million in 2025.

Sentiment

Score: 5

Explanation: The report presents mixed signals. While there's a decrease in revenue and operating income, the company is taking steps to improve efficiency and has appointed a new CEO. The sentiment is neutral as the negative financial results are somewhat balanced by positive strategic changes.

Positives

• Recurring contract value increased at March 31, 2025 compared to December 31, 2024 as year-to-date new sales surpassed year-to-date losses.
• The company believes the expansion of its product and services portfolio during 2024, along with a broader sales effort, led to improved sales and retention in the fourth quarter compared with the prior several quarters.
• The company is in compliance with its financial covenants under the Credit Agreement as of March 31, 2025.
• The company has access to a $30.0 million revolving credit facility and a $110.0 million delayed draw-down term facility.

Negatives

• Revenue decreased by 5% compared to the same period last year.
• Operating income decreased by 2% compared to the same period last year.
• Recurring Contract Value (TRCV) decreased by 4% compared to the same period last year.
• Cash provided by operating activities decreased by 47% compared to the same period last year.
• The company had a working capital deficit of $17.4 million as of March 31, 2025.

Risks

• The possibility of non-renewal of client service contracts, reductions in services purchased or prices, and failure to retain key clients.
• The company's ability to compete in its markets, which are highly competitive with new market entrants, and the possibility of increased price pressure and expenses.
• The possibility that the company's solutions and technology do not perform as expected.
• The possibility that the company's acquisitions and partnerships do not achieve the increased demand/profitability expected.
• The likelihood that a pandemic or global conflicts will adversely affect the company's operations, sales, earnings, financial condition and liquidity.
• The effects of an economic downturn.
• The impact of consolidation in the healthcare industry.
• The impact of federal healthcare and budget legislation, executive orders, cost-saving measures, and other regulatory changes.
• The company's ability to attract and retain key managers and other personnel.
• The possibility that the company's intellectual property and other proprietary information technology could be copied or independently developed by its competitors.
• The company's ability to maintain effective internal controls.
• The possibility for failures or deficiencies in the company's information technology platform.
• The possibility that the company or its third-party providers could be subject to cyber-attacks, security breaches or computer viruses.

Future Outlook

The company expects operating income and margin to increase in the near term due to revenue and cost initiatives, excluding the impact of executive compensation charges. The company estimates future costs related to headquarters building renovations to be $3.7 million in 2025, which it expects to fund through operating cash flows and borrowings on the Revolving Loan and Delayed Draw Term Loan.

Management Comments

• The company believes the expansion of its product and services portfolio during 2024, along with a broader sales effort, led to improved sales and retention in the fourth quarter compared with the prior several quarters.
• The company views total Recurring Contract Value, or TRCV, a measure of revenue under all renewable contracts for their respective annual renewal periods, as a leading indicator of revenue expectations.
• The company believes that its existing sources of liquidity, including cash and cash equivalents, borrowing availability, and operating cash flows will be sufficient to meet its projected capital and debt maturity needs for the foreseeable future.

Industry Context

The report mentions consolidation in the healthcare industry as a factor that could affect the company's results. The company's focus on patient experience and engagement aligns with the industry's shift towards value-based care and patient-centric models.

Comparison to Industry Standards

• It is difficult to compare NRC Health's results directly to industry standards without knowing the specific segments in which it competes and the performance of its direct competitors.
• Companies like Press Ganey and Huron Consulting Group also provide services related to patient experience and healthcare consulting, but their financial reporting may not be directly comparable.
• The company's recurring revenue model is common in the software and services industry, and its retention rate is a key indicator of its competitive strength.
• The company's debt levels and financial covenants are typical for companies of its size and industry.

Management Changes

Legal Proceedings

• The company is involved in certain claims and litigation arising in the normal course of business, but it does not believe the final disposition of these claims will have a material adverse effect on its consolidated financial position, results of operations or liquidity.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and operating income, but the stock repurchase program and new CEO appointment could be viewed positively.
• Employees may be affected by workforce reductions and changes in executive compensation.
• Customers may benefit from the company's continued investment in its Human Understanding solutions.
• Creditors are protected by the company's compliance with its financial covenants.

Next Steps

• Trent Green will assume the role of CEO on June 1, 2025.
• The company will continue to execute its stock repurchase program.
• The company will continue to invest in its Human Understanding solutions.
• The company will complete building renovations to its headquarters in 2025.

Key Dates

Keywords

financial results, recurring contract value, revenue, CEO appointment, healthcare analytics, patient experience, NRC Health